Pharmaceutical formulations for inducing specific immunity against SARS-COV-2
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A pharmaceutical preparation, a specific technology, applied in the fields of immunology, virology, and biotechnology, which can solve problems such as ineffectiveness of vaccines
Pending Publication Date: 2022-07-08
View PDF4 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0017] A great disadvantage of this solution is related to the fact that the vaccine may not be effective in some populations due to pre-existing immunity against human adenovirus type 5
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
example 1
[0256] Preparation of expression vectors containing the genome of recombinant human adenovirus serotype 26.
[0257] In the first stage, the design of the plasmid construct pAd26-Ends was proposed. It carries two regions of homology to the genome of recombinant human adenovirus serotype 26 (two homology arms) and an ampicillin resistance gene. One of the homology arms is the start of the genome of recombinant human adenovirus serotype 26 (from the left inverted terminal repeat to the E1 region) and the viral genome sequence containing the pIX protein). The other homology arm contains the nucleotide sequence located after the ORF3 E4 region until the end of the genome. The synthesis of the pAd26-Ends construct was carried out by the Moscow company "Eurogen" ZAO (Moscow company "Eurogen" ZAO).
[0258] Human adenovirus serotype 26 DNA isolated from virions was mixed with pAd26-Ends. The plasmid pAd26-dlE1 carrying the genome of human adenovirus serotype 26 with the deleted E1...
example 2
[0271] An immunobiological preparation in the form of an expression vector was produced based on the genome of recombinant human adenovirus serotype 26, in which the E1 and E3 regions were deleted and the ORF6-Ad26 region was replaced by ORF6-Ad5, in which the group selected from SEQ ID NO: 1, SEQ ID NO: 1, SEQ ID NO: 1 was integrated. : 2. The expression cassette of SEQ ID NO: 3.
[0272] At this stage, the expression vector obtained in Example 1 was purified using anion exchange and size exclusion chromatography. The final suspension contains adenoviral particles in a buffered solution for liquid formulations of pharmaceutical formulations or in buffered solutions for lyophilized (lyophilized) formulations of pharmaceutical formulations.
[0273] Therefore, the following immunobiologics were generated based on the genome of recombinant human adenovirus serotype 26, in which the E1 and E3 regions were deleted and the ORF6-Ad26 region was replaced by ORF6-Ad5:
[0274] 1. An ...
example 3
[0282] Preparation of expression vectors containing the genome of recombinant simian adenovirus serotype 25.
[0283] In the first stage, the design of the plasmid construct pSim25-Ends was proposed. It carries two regions of genome homology to the simian adenovirus serotype 25 (two homology arms). One of the homology arms is the start of the genome of simian adenovirus serotype 25 (from the left inverted terminal repeat to the E1 region) and the sequence from the end of the E1 region to the pIVa2 protein. The other homology arm contains sequences at the end of the adenoviral genome, including the right inverted terminal repeat. The synthesis of the pSim25-Ends construct was carried out by the Moscow company "Eurogen" ZAO.
[0284] The DNA of simian adenovirus serotype 25 isolated from virions was mixed with pSim25-Ends. Through the process of homologous recombination between pSim25-Ends and viral DNA, plasmid pSim25-dlE1 was obtained, which carries the genome of simian ade...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
weight
aaaaa
aaaaa
Login to view more
Abstract
The present invention relates to biotechnology. The claimed agents can be used for the prevention of SARS-CoV-2. A pharmaceutical formulation is created which contains a component (1) comprising an agent in the genomic form of a recombinant human adenovirus serotype (26) in which an expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 is placed, and which further contains a component (2) comprising an agent in the genomic form of a recombinant human adenovirus serotype (5) in which an expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 is placed. Furthermore, a pharmaceutical formulation is created which contains a component 1 comprising an agent in the genomic form of a recombinant human adenovirus serotype (26) in which an expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 is placed, and which further contains a component (2) comprising an agent in the genomic form of a recombinant simian adenovirus serotype (25) in which an expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 is placed, wherein an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2 and SEQ ID NO: 3 is placed. Furthermore, a pharmaceutical formulation is created which contains component 1 comprising an agent in the genomic form of a recombinant simian adenovirus serotype (25) in which an expression cassette selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 is placed, and which further contains component (2) comprising an agent in the genomic form of a recombinant human adenovirus serotype (5) in which an expression cassette selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 is placed, wherein an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 is placed.
Description
technical field [0001] The present invention relates to biotechnology, immunology and virology. The claimed agent can be used to prevent disease caused by the severe acute respiratory syndrome virus SARS-CoV-2. Background technique [0002] At the end of 2019, an outbreak of atypical pneumonia of unknown etiology broke out in Wuhan, the capital of Hubei Province (People's Republic of China). Studies conducted by researchers have shown that the outbreak is caused by a single-stranded RNA virus belonging to the family Coronaviridae, lineage B betacoronavirus (beta-CoVB). On February 11, 2020, the World Health Organization officially named the new virus SARS-CoV-2 and the disease it causes COVID-19 (“Coronavirus Disease 2019”). [0003] Within a few months, SARS-CoV-2 had spread around the world and became an epidemic affecting more than 200 countries. As of August 1, 2020, the number of cases exceeded 17,500,000 and the number of deaths was 683,000. [0004] Coronaviruses ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more